Qinlock (ripretinib tablets) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has metastatic or unresectable disease
• Patient has an activating KIT mutation
• Patient has tried at least ONE systemic regimen (e.g., Opdivo + Yervoy, Opdualag, Keytruda, Opdivo, Tafinlar + Mekinist, Zelboraf + Cotellic, Braftovi + Mektovi)

Approval duration

1 year